BridgeMD
New treatment option for Squamous Cell Carcinoma of the Oropharynx
Official title Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
ClinicalTrials.gov ID: NCT06061705
What this study is testing
- What it's testing
- Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodigestive Tract (UAT) have a poor prognosis, with a 10-year survival rate of no more than 20%.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged ≥ 18 years
- Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx
- Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy
- Patient affiliated to a health insurance plan
- French-speaking patient
You likely can't join if
- Patients with a contraindication to immunotherapy (transplant patients)
- Pregnant or breast-feeding patients
- Patient under guardianship or curatorship
- Patient under court protection
- Patient deprived of liberty
See the full eligibility criteria
- Patients aged ≥ 18 years
- Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx
- Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy
- Patient affiliated to a health insurance plan
- French-speaking patient
- Patient with free, informed and written consent
- Patients with a contraindication to immunotherapy (transplant patients)
- Pregnant or breast-feeding patients
- Patient under guardianship or curatorship
- Patient under court protection
- Patient deprived of liberty
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.